P. Tobin

The Importance of Tumor Glucuronidase in the Activation of Irinotecan in a Mouse Xenograft Model

H. Dodds, P. Tobin, C. Stewart, 2002, Journal of Pharmacology and Experimental Therapeutics.

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea.

S. Clarke, Rohini Sharma, P. Tobin, 2005, The Lancet. Oncology.

A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer

P. Beale, S. Clarke, P. Tobin, 2006, Cancer Chemotherapy and Pharmacology.

The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.

S. Clarke, P. Tobin, L. Rivory, 2005, British journal of clinical pharmacology.

Loperamide inhibits the biliary excretion of irinotecan (CPT‐11) in the rat isolated perfused liver

A. McLachlan, P. Tobin, L. Rivory, 2005, The Journal of pharmacy and pharmacology.

The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours.

S. Clarke, H. Dodds, P. Tobin, 2003, Oncology reports.

Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro

P. Wielinga, W. London, S. Cohn, 2005, Molecular Cancer Therapeutics.